Combining forces in metabolic disorders

Last week’s successful showing of Altimmune’s GLP-1/glucagon dual receptor agonist in an early-stage obesity trial has prompted the group to lay out further plans for the molecule in obesity and Nash.

But there are nearly a dozen double or triple combo projects in development for these metabolic disorders. Lilly is the most prominent company here, with involvement in three programmes. The most advanced, tirzepatide, could soon be filed in diabetes with obesity not far behind. Altimmune has a long fight for market share ahead of it.